Invasive coronary imaging of inflammation to further characterize high-risk lesions: what options do we have?
- PMID: 38370159
- PMCID: PMC10871865
- DOI: 10.3389/fcvm.2024.1352025
Invasive coronary imaging of inflammation to further characterize high-risk lesions: what options do we have?
Abstract
Coronary atherosclerosis remains a leading cause of morbidity and mortality worldwide. The underlying pathophysiology includes a complex interplay of endothelial dysfunction, lipid accumulation and inflammatory pathways. Multiple structural and inflammatory features of the atherosclerotic lesions have become targets to identify high-risk lesions. Various intracoronary imaging devices have been developed to assess the morphological, biocompositional and molecular profile of the intracoronary atheromata. These techniques guide interventional and therapeutical management and allow the identification and stratification of atherosclerotic lesions. We sought to provide an overview of the inflammatory pathobiology of atherosclerosis, distinct high-risk plaque features and the ability to visualize this process with contemporary intracoronary imaging techniques.
Keywords: atherosclerosis; inflammation; intravascular ultrasound; near-infrared fluorescence imaging; near-infrared spectroscopy; optical coherence tomography.
© 2024 Los, Mensink, Mohammadnia, Opstal, Damman, Volleberg, Peeters, van Royen, Garcia-Garcia, Cornel, El Messaoudi and van Geuns.
Conflict of interest statement
PD: received research grants and speaker fees from Abbott Vascular; research grants, speaker fees and consultancy fees from Philips; and research grants from AstraZeneca. NvR: research grants from Abbott, Philpis, Biotronik and Medtronic. Speaker fee: Abbott, Bayer, Rainmed, Microport. HG-G: receives consulting fees from Boston Scientific, Abbott and institutional grants from Phillips, Biotronik, Abbott, MedAlliance, Corflow, Chiesi and Medis. JC: Advisory board Amgen en Novo Nordisk. Received research grants from ZonMw. R-JvG: reported grants and personal fees from Boston Scientific, grants and personal fees from Abbott Vascular, grants and personal fees from Astra Zeneca, grants and personal fees from Amgen, grants from InfraRedx. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
Publication types
LinkOut - more resources
Full Text Sources
